Cytogenetics and its prognostic value in myelodysplastic syndromes.
In this review we describe the cytogenetics of primary and secondary myelodysplastic syndromes, discuss their relationship with other hemopoietic malignancies, and also attempt to put the described chromosome abnormalities into a clinically more useful perspective by emphasizing the prognostic impact they carry. In addition, we discuss their use as clonal markers in determining the mode of action and efficiency of different therapeutic approaches.
Verhoef
G E
GE
Department of Hematology, University Hospital Leuven, Belgium.
Boogaerts
M A
MA
D002869:Chromosome Aberrations / Q000175:diagnosis*; D025063:Chromosome Disorders; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D009190:Myelodysplastic Syndromes / Q000175:diagnosis*; D011379:Prognosis; D016019:Survival Analysis
D006133:Growth Substances